All News
Sjögren's disease RCTs: Has the Long Drought Ended?
Sjögren's disease has been a difficult space for new FDA approvals. At ACR 2025, two late breaking abstracts have triggered hope for patients suffering from Sjögren's disease.
Read Article
Tacrolimus in Lupus Nephritis Management
Prof. Sandra Navarra and colleagues compared the efficacy and safety of tacrolimus and glucocorticoids vs. mycophenolate mofetil (MMF) as a continuous induction-maintenance treatment for class III/IV+V lupus nephritis.
Read Article
ACR 2025 Rheumatology Round Up
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.
Read Article
Tofacitinib in AxSpA in Developing Countries
Dr. Antoni Chan reports on abstracts 0582 and abstract 0554 presented at #ACR25
https://t.co/4kTv90PhIC https://t.co/WRUBP0O21b
Links:
Dr. John Cush RheumNow ( View Tweet)
900,000 vs 9
It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed.
It takes less than nine minutes to make your patient feel seen, understood and reassured.
If you skip the 9 minutes, you wasted the https://t.co/DBoteUTavZ
Dr. John Cush RheumNow ( View Tweet)
Topline results of ALLEGORY study (Genentech) - 300 pt. phase 3 DBRPCT obinuntuzumab vs PBO in active SLE w/ SRI-4 primary outcome at wk 52. The anti-CD20, B-cell depleter, Rx met all efficacy endpoints primary and all key secondary endpoints. Gazyva was FDA approved last wk https://t.co/Wd6EFEjvGP
Dr. John Cush RheumNow ( View Tweet)
Difficult to Manage axSpA
Drs. Antoni Chan and Rodrigo Garcia Salinas discuss abstract 0584, "Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns", presented at #ACR25 https://t.co/84HZojI3FJ
Dr. John Cush RheumNow ( View Tweet)
FDA is going to "fast-track" biosimilars to curtail the costs of expensive biologics https://t.co/h5NBsUaM97
Dr. John Cush RheumNow ( View Tweet)
Not only lovely work @TheLancetRheum from @jeffsparks and friends, but they have some AI imaging work up tomorrow from the same SAIL-RA cohort, showing the spectrum of impact in all RA patients, using radiomics.
Check it out #ACR25 ABST1751 @RheumNow
https://t.co/TlmHOOpNNp https://t.co/P62RXI8ePQ
Links:
David Liew drdavidliew ( View Tweet)
A 15-year-old girl has short stature and the hand finding shown . Labs show ↓Ca²⁺, ↑PO₄³⁻, ↑PTH.
What is the most likely diagnosis? https://t.co/afPUeaqfZT
Dr. Nikhil Agrawal DrNikhilMD ( View Tweet)
If you missed this pattern, you missed an autoimmune classic
What’s it? https://t.co/zO48zPCkqP
DocXus docxusofficial ( View Tweet)
#ACR25 Abstract 1526
“Guidance for #Steroid Tapering in Systemic Lupus Erythematosus”
101 international experts reached Delphi consensus on CS tapering strategies in #SLE.
🔹 Practical guidance for real-world tapering across disease activity levels and organ involvement. https://t.co/GRlUz3Y3EP
Links:
Romatolog Nurullah_Akkoc ( View Tweet)
🍼 “Stop breastfeeding if on methotrexate” — that’s what we’ve always heard.
But here’s the news 👇
📊 Latest EULAR lactation: Methotrexate = LoE 4 / C
➡️ May be considered in breastfeeding if no safer alternative exists.
💡Not first-line, not forbidden — just evidence-limited. https://t.co/IJEpZYMaFV
Dr Abhilasha Manwatkar (AIIMS Nagpur) Abhilasha21822 ( View Tweet)
@Janetbirdope’s #ACR25 pearls remind us:
Order ANA only when clinical suspicion exists
Never repeat a positive ANA
ENA only if ANA+
❌ Ignore dsDNA if ANA– (except anti-Ro52)
Stop serial dsDNA/C3/C4 if stable
Smart lab use saves patients anxiety and systems money.
#SLE https://t.co/Mu3EefcIx0
Romatolog Nurullah_Akkoc ( View Tweet)
Really great visual summaries by Athena Chin, Sam Whittle and colleagues: Recs for the Use DMARDs in Pregnancy and Reproductive Health for Pts w Rheumatic Disease: A Scoping Review - Oct 2025 - Arthritis Care & Research #Rheumatology #MedEdu https://t.co/zRJcTESJWN 🇦🇺 https://t.co/OYZVtLEYr7
Links:
Suleman Bhana, MD DrBhana ( View Tweet)
Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus
📄 Read the paper: https://t.co/56eOK86lmn
ℹ️ See additional content and resources on this guideline at https://t.co/PVEyOkY14w https://t.co/cR4RVfWPlI
Links:
ACR_Journals ACR_Journals ( View Tweet)
Early Peripheral SpA: Is it okay to stop treatment sometimes?
Dr. Richard Conway reports on abstract 0568 "Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial," presented at #ACR25
https://t.co/FtI2o90v9O https://t.co/jUAEDZhDW5
Dr. John Cush RheumNow ( View Tweet)
Is Low Disease Activity Low Enough?
Drs. Jonathan Kay and Joel Kremer discuss abstract 0449, "Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life". #ACR25 https://t.co/kI8qOYjVL4
Dr. John Cush RheumNow ( View Tweet)
GLP-1 Receptor Agonists: Impacts Beyond Metabolism?
Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our https://t.co/Xl6M3xSvlq
Dr. John Cush RheumNow ( View Tweet)
The Rapidly Evolving Landscape of Cellular and Immune-based Therapies
When Henry Ford unveiled the Model T in 1908, the automobile industry was forever changed. A similar transformation is now underway in rheumatology, where cellular and immune therapies are redefining how we https://t.co/RQuVETSTG4
Dr. John Cush RheumNow ( View Tweet)
